Cryptosporidium parvum is a protozoan parasite that causes mild to severe diarrheal disease in animals and humans. There are currently no effective chemotherapeutic agents available for the treatment of cryptosporidiosis. Recent studies have described small, naturally occurring antimicrobial lytic peptides with antiprotozoal activities. In the present study, the anticryptosporidial activities of three synthetic lytic peptides were determined in an in vitro sporozoite susceptibility assay. Sporozoite viability was assessed microscopically by the uptake of the vital dyes fluorescein diacetate and propidium iodide. Sporozoite viability was reduced by 93.5% following a 60-min exposure to 10 ,uM Hecate-1 at 37°C. Shiva-10 reduced sporozoite viability by approximately 74.0% after a 60-min exposure at 100 ,M and 37°C. The cecropin-b analog SB-37 reduced sporozoite viability by 6.0% following a 60-min exposure at 100 ,uM and 37°C. A control peptide showed no anticryptosporidial activity.
Cryptosporidium parvum, an enteric protozoan parasite, colonizes the mucosal epithelium of the gastrointestinal tracts of a wide range of mammals causing a mild to severe, cholera-like diarrhea. The disease is especially pronounced in neonatal and immunocompromised hosts. More than 90 chemotherapeutic agents and therapeutic regimens have been tested in humans and animals infected with C. parvum without success. The lack of effective therapies for the control of cryptosporidiosis is of grave consequence for individuals who develop chronic, severe cryptosporidial diarrhea (6, 14) .
The discovery of lytic peptides (cecropins) in the giant silk moth (3) and the identification of lytic peptides (magainins) in the skin of frogs (16) has opened a new area of research into antimicrobial compounds. The amphipathic proteins that constitute this new class of agents are generally very small, less than 36 amino acids (molecular weight [MW] , <4,000), and apparently fold into helices with hydrophilic and hydrophobic faces, facilitating their interactions with cell membranes (3) . Cecropin, magainin, and synthetic analogs of these molecules form ion channels in the membranes of cells or in synthetic planar lipid membranes (5, 7, 15) . Studies by Jaynes et al. (9) demonstrating activities of synthetic lytic peptides against the eucaryotic protozoan parasites Plasmodium falciparum and Trypanosoma cruzi encouraged us to examine the peptides for possible activity against C. parvum.
MATERIALS AND METHODS
Lytic and control peptides. Lytic and control peptides were synthesized and purified at Louisiana State University as previously described (9) . Briefly, peptides were synthesized on a Biosearch Sam Two peptide synthesizer with a 4-methyl benzhydral amine resin with a COOH-terminal amide. Peptide preparations were greater than 95% pure after application to size-exclusion chromatographic columns and highperformance liquid chromatographic columns. The peptides were supplied for assessment as randomly numbered, * and Shiva-10 are synthetic, amphipathic peptides, 23 amino acids long, which makes them the same length as the naturally occurring magainin peptides. Biochemically, Hecate-1 is a shortened, melittin-type peptide, while Shiva-10 is a shortened, cecropin-type peptide. However, there are no amino acid sequence homologies between naturally occurring melittin or cecropins and the synthetic peptides Hecate-1 and Shiva-10 (4). C. parvum sporozoite viability was reduced by 93.5% after a 60-min exposure to Hecate-1 at a 10 ,M concentration (25.4 ,ug/ml). Shiva-10 reduced sporozoite viability by 74.0% after a 60 min exposure at a 100 ,uM concentration (254.0 ,ug/ml). Hecate-1 was approximately 10-to 50-fold more active than Shiva-10 on a micromolar basis. That is, to achieve the same reduction in viability (74.0%) after a 60-min exposure at 37°C, sporozoites would have to be exposed to a 2 to 10 ,uM Hecate-1 solution versus a 100 ,uM Shiva-10 solution.
The parasiticidal effects exhibited by Hecate-1 and Shiva-10 were produced at concentrations similar to those of magainin-2 reported to be bactericidal or fungicidal (10 to 500 ,ug/ml) in vitro (13) . The in vivo antisporogonic activity of magainin-2 against Plasmodium cynomolgi and Plasmodium knowlesi (8) was manifest at 20-to 40-fold-higher peptide concentrations (500 to 1,000 ,ug/ml) than the in vitro antisporozoite activity of Hecate-1 demonstrated in the present study (2.5 to 25 ,uglml).
The 38-amino-acid cecropin analog, SB-37, showed low activity against C. parvum sporozoites. After an exposure of 60 min to a 100 jiM solution of the peptide, SB-37 reduced sporozoite viability by a mere 6.0%. This is in contrast to the reported activity of SB-37 against both T. cruzi and P. falciparum, for which significant in vitro activities were observed at a peptide concentration of 50 jiM (9) .
Recent studies have demonstrated the presence of lytic peptides in the guts of pigs and mice (11, 12) . These reports implicate lytic peptides in the natural defense of the intestinal tract against bacterial infection, suggesting that lytic peptides may be useful as antimicrobial agents in the gut. Lee et al. (11) isolated a cecropinlike peptide from the small intestines of pigs that exhibited potent antibacterial properties, especially against gram-negative bacteria. They also isolated an endocrine protein, determined to be essentially identical to vasoactive intestinal peptide, with activity against gram-positive bacteria. Ouellette et al. (12) described the presence of cryptdin, a corticostatin-defensin lytic peptide, in Paneth cells within the mouse small intestine. Cryptdin mRNA was absent from the duodenum, colon, and liver. Conventionally reared, germfree, and athymic nude mice exhibited equally abundant cryptdin mRNA levels in the small intestine, which indicates that mRNA levels are independent of T-cell mediation and the presence of lumenal bacteria. Ouellette et al. conclude that the gut mRNA levels may support the synthesis of cryptdin in quantities sufficient for defensinlike activity in the lumen. In support of this conclusion, the investigators point out that there are far fewer bacteria in the small intestine than in the colon. Cryptdin was also reported to be developmentally regulated, essentially absent at birth and not expressed at adult levels until the mice reached 3 to 4 weeks of age. It is of particular interest that this age-related expression coincides with the period of susceptibility to C. parvum in laboratory mice. After 3 weeks of age, immunocompetent laboratory mice are essentially refractory to cryptosporidial infections (14) .
The synthetic lytic peptides Hecate-1 and Shiva-10 exhibited significantly higher anticryptosporidial activities than the cecropin analog SB-37. This suggests that by varying the amino acid sequence and length, it may be possible to develop synthetic peptides with high activity for target pathogens. The antimicrobial activities of naturally occurring lytic peptides in the mammalian gut may be augmented through the administration of highly active, pathogen-specific synthetic peptides.
One concern regarding the potential application of lytic peptides in vivo is the potential for enteric and/or systemic toxicity. Orally administered peptides may circumvent the risk of systemic toxicity because the peptides are sufficiently large to prevent translocation across the gut epithelium. Further study is necessary to characterize the potential toxicities and the in vivo activities of Hecate-1 and Shiva-10 against C. parvum. Given the present absence of therapeutic agents for the control of cryptosporidial infections, the anticryptosporidial activities of natural and synthetic lytic peptides warrant further investigation.
